retatrutide fda approval status november 2025 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide Dosing Guide: 1-12 mg

Mochi Health Mochi charges a lower membership and flat compounded medication prices

Zepbound / Tirzepatide Zepbound is a weekly GIP/GLP-1 medication that may provide strong appetite and metabolic support for selected patients

HR decision-makers are closely following the surge in demand for the medications, intently considering their plans, and seeking more information from trusted sources to help them reach a decision

A provider who cuts corners might sell a vial labeled "10 mg" that contains significantly less of the target peptide

There is no wrong choice between these medications for most candidates

Notably, North Carolina removed and subsequently reinstated coverage between August 2024 and January 2025